CervoMed to report 32-week extension phase results for DLB treatment

BOSTON - CervoMed Inc. (NASDAQ:CRVO), whose shares have surged nearly 250% over the past six months, will host a conference call on Monday at 8:00 AM ET to share primary endpoint results from the 32-week extension phase of its Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies (DLB), the company announced Thursday.

The clinical-stage company, which focuses on developing treatments for age-related neurologic disorders and maintains a strong liquidity position with a current ratio of 9.78, will present the new data following late-breaking presentations at the Alzheimer’s Association International Conference 2025. According to InvestingPro data, three analysts have recently revised their earnings expectations upward for the upcoming period.

The RewinD-LB study is a randomized, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod in 159 patients with DLB. The 16-week initial phase was followed by a 32-week extension phase in which all participants received the investigational treatment.

The study excluded patients with Alzheimer’s disease co-pathology, as assessed by plasma ptau181 levels. According to the company, patients with pure DLB may comprise up to 50% of the diagnosed DLB patient population.

Primary outcome measures include change in the Clinical Dementia Rating - Sum of Boxes, with secondary endpoints covering cognitive tests and functional assessments.

The study is primarily funded by a $21.3 million grant from the National Institutes of Health’s National Institute on Aging and includes 43 sites across the United States, United Kingdom, and Netherlands.

Neflamapimod is an orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha and is being investigated for its potential to treat synaptic dysfunction in neurodegenerative disorders.

The announcement was made in a company press release statement. With a market capitalization of approximately $70 million and significant recent momentum, CervoMed shows promising potential. InvestingPro subscribers can access 10+ additional investment tips and detailed financial metrics to make more informed investment decisions about CRVO.

In other recent news, CervoMed announced its financial results for the first quarter of 2025, revealing a cash position of $35.2 million, including cash equivalents and marketable securities. This financial standing is expected to sustain the company’s operations until mid-2026, supported by anticipated grant funds from the National Institute on Aging. Chardan Capital Markets has maintained its Buy rating for CervoMed shares, setting a price target of $15.00. CervoMed has also reported overcoming a major challenge with its lead asset, neflamapimod, aimed at treating dementia with Lewy Bodies. After previous setbacks in December 2024, where the drug did not meet the primary or secondary endpoints in the RewinD-LB study, recent positive data emerged from the Open-Label Extension phase. The company attributed the earlier negative results to the use of expired capsules rather than the drug’s effectiveness. These developments mark important progress for CervoMed in its ongoing research and financial planning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.